VivoSeq
Cardiovascular

Cardiovascular Surgery

0

Pipeline Programs

4

Active Trials

4

Companies Involved

Cardiovascular Surgery is an early-stage landscape with 0 programs across 4 companies. The most active players are Nabi Biopharmaceuticals, Quark Pharmaceuticals, CSL Behring.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

14

clinical trials

Completed8 · 57%
Recruiting2 · 14%
Unknown status2 · 14%
Enrolling by invitation1 · 7%
Not yet recruiting1 · 7%

Trial Activity

14 trials

Clemastine in Cardiovascular Surgery
Completed··N/A·NCT03826004·100 enrolled
StaphVAX in Cardiovascular Surgery Patients
Completed·NNabi Biopharmaceuticals·Phase 3·NCT00211913·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)